Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis

被引：431
|
作者：
Kuo, Phillip H.
Kanal, Emanuel
Abu-Alfa, Ali K.
Cowper, Shawn E.
机构：
[1] Yale Univ, Sch Med, Dept Diagnost Radiol, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, New Haven, CT 06520 USA
[3] Yale Univ, Sch Med, Dept Dermatol & Pathol, New Haven, CT 06520 USA
[4] Univ Pittsburgh, Med Ctr, Dept Radiol, Pittsburgh, PA USA
来源：
RADIOLOGY | 2007年 / 242卷 / 03期
关键词：
D O I：
10.1148/radiol.2423061640
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
While at this time there are more questions than answers, the recognition of an epidemiologic association between the administration of gadolinium-based MR contrast agents and the development of nephrogenic systemic fibrosis prompts caution in the use of these agents in the setting of renal disease. © RSNA, 2007.
引用
收藏
页码：647 / 649
页数：3
相关论文
共 50 条
  • [21] ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis
    Henrik S. Thomsen
    European Radiology, 2007, 17 : 2692 - 2696
  • [22] Nephrogenic systemic fibrosis and gadolinium contrast agents
    Aguilera, Cristina
    Agusti, Antonia
    MEDICINA CLINICA, 2011, 136 (14): : 643 - 645
  • [23] Strong association between the use of gadolinium-based contrast agents with nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis - Reply
    Cheung, P. P. M.
    Raj, A. K. Dorai
    INTERNAL MEDICINE JOURNAL, 2007, 37 (07) : 509 - 509
  • [24] Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: The role of excess ligand
    Sieber, Martin A.
    Lengsfeld, Philipp
    Walter, Jakob
    Schirmer, Heiko
    Frenzel, Thomas
    Siegmund, Fred
    Weinmann, Hanns-Joachim
    Pietsch, Hubertus
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2008, 27 (05) : 955 - 962
  • [25] Influence of excess ligand on Nephrogenic Systemic Fibrosis associated with nonionic, linear gadolinium-based contrast agents
    Semelka, Richard C.
    Prybylski, John P.
    Ramalho, Miguel
    MAGNETIC RESONANCE IMAGING, 2019, 58 : 174 - 178
  • [26] Nephrogenic systemic fibrosis: UK survey of the use of gadolinium-based contrast media
    Rees, O.
    Agarwal, S. K.
    CLINICAL RADIOLOGY, 2010, 65 (08) : 636 - 641
  • [27] Nephrogenic systemic fibrosis and gadolinium-based contrast: Medico-legal implications
    Houck, Cara M.
    Pristave, Robert J.
    Kannensohn, Kimberly J.
    SEMINARS IN DIALYSIS, 2008, 21 (02) : 166 - 170
  • [28] Nephrogenic systemic fibrosis and gadolinium-based contrast: What's a nephrologist to do?
    Perazella, Mark A.
    SEMINARS IN DIALYSIS, 2008, 21 (02) : 121 - 122
  • [29] Risk of Nephrogenic Systemic Fibrosis Is Low in Patients With Chronic Liver Disease Exposed to Gadolinium-Based Contrast Agents
    Smorodinsky, Emmanuil
    Ansdell, David S.
    Foster, Zeke W.
    Mazhar, Sameer M.
    Cruite, Irene
    Wolfson, Tanya
    Sugay, Sebastian B.
    Iussich, Gabriella
    Shiehmorteza, Masoud
    Kono, Yuko
    Kuo, Alexander
    Sirlin, Claude B.
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2015, 41 (05) : 1259 - 1267
  • [30] Gadolinium-based contrast agents, erythropoietin and nephrogenic systemic fibrosis in patients with end-stage renal failure
    Pieringer, Herwig
    Schumacher, Sabine
    Schmekal, Bernhard
    Gitter, Thomas
    Biesenbach, Georg
    CLINICAL KIDNEY JOURNAL, 2008, 1 (03): : 193 - 194
12345